CoChat

Novel therapeutics in hypertriglyceridemia

Gryn, Steven E., Hegele, Robert A. · 2015 · Current Opinion in Lipidology

The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

PURPOSE OF REVIEW: We provide an overview of recent advances in the therapy of hypertriglyceridemia, focusing on several new therapies with potential for treating of familial chylomicronemia, other forms of hypertriglyceridemia, and for triglyceride-lowering in patients with other lipid disorders. RECENT FINDINGS: Newer triglyceride-lowering modalities under evaluation include gene therapy for lipoprotein lipase deficiency (alipogene tiparvovec), and antisense oligonucleotides against mRNA for apolipoproteins B (mipomersen) and C3 (volanesorsen, ISIS 304801). Other potential therapies include small molecule inhibitors of microsomal triglyceride transfer protein (lomitapide) and diacylglycerol acyltransferase-1 (pradigastat), and a monoclonal antibody against angiopoietin-like protein 3 (REGN1500). There is also renewed interest in omega-3 fatty acids, and in developing potent and selective agonists of peroxisome proliferator-activated receptors. SUMMARY: Several promising triglyceride-lowering therapies are at various stages of development; a few are even available in some markets. Although existing data suggest good biochemical efficacy, data on long-term clinical outcomes are still limited. For some therapies, cost will be an important consideration, and use will likely be restricted to orphan indications, for example very severe cases of hypertriglyceridemia as seen in familial chylomicronemia syndrome, although some therapies could theoretically be more broadly used one day for cardiovascular disease prevention.

Overview

Integrity signals

Registry

Crossref · 10.1097/mol.0000000000000231

Cites

57 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 58 references

Research works printed but not linked: 2

  1. Pirillo, 2015, Drug Des Devel Ther, 9, 2129
  2. Goldberg, 2012, Drug Des Devel Ther, 6, 251

Cited by

See all 44

Metadata

Authors
Gryn, S. E., & Hegele, R. A.
Affiliations
Western University (CA)
Corresponding author
Gryn, Steven E.
Venue
Current Opinion in Lipidology
Published
2015-12
Volume
26
Issue
6
Pages
484-491
ISSN
0957-9672 (ISSN-L)
OpenAlex
W2415852003
Cited by
44
References
59
Citations by year
2026: 1 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 9 · 2018: 4 · 2017: 5 · 2016: 8
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Lipidology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Pfizer
  • AstraZeneca
  • Canadian Institutes of Health Research (79523_1, MOP13430)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
hypertriglyceridemia, familial chylomicronemia syndrome, triglyceride-lowering therapy, lipoprotein lipase deficiency, antisense oligonucleotides, mipomersen, volanesorsen, microsomal triglyceride transfer protein inhibitor, lomitapide, ANGPTL3, omega-3 fatty acids, peroxisome proliferator-activated receptor agonists, apolipoprotein B, apolipoprotein C-III
MeSH terms
Animals, Hypolipidemic Agents, Humans, Hypertriglyceridemia, Genetic Therapy, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel therapeutics in hypertriglyceridemia. https://app.cochat.ai/papers/10.1097/mol.0000000000000231
The paper
Gryn, S. E., & Hegele, R. A. (2015). Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0000000000000231

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.